共 177 条
[1]
Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]
Miller KD(2016)The changing incidence of thyroid cancer Nat Rev Endocrinol 12 646-653
[3]
Jemal A(2015)Germline HABP2 mutation causing familial nonmedullary thyroid cancer N Engl J Med 373 448-455
[4]
Kitahara CM(2017)Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma Ann Oncol 28 2813-2819
[5]
Sosa JA(2017)Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies Nat Rev Endocrinol 13 644-660
[6]
Gara SK(2016)Thyroid cancer Lancet 388 2783-2795
[7]
Jia L(2009)Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin Cancer Res 69 7311-7319
[8]
Merino MJ(2018)Early evolutionary divergence between papillary and anaplastic thyroid cancers Ann Oncol 29 1454-1460
[9]
Schlumberger M(2014)Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Lancet 384 319-328
[10]
Elisei R(2015)Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status BMC Cancer 15 184-20